Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US FDA May Change Requirements For CV Outcomes Trials For Type 2 Diabetes Drugs

Sep 18 2018

• By Brenda Sandburg

Diabetes

Related Content

Novo Nordisk's Victoza Adds CV Benefit Claim, But Not For Primary Prevention

Aug 28 2017

FDA’s Diabetes Guidance On CV Risk Will Get First Test With Pending NDAs

Dec 22 2008

FDA Should Require Cardiovascular Outcomes Trials For All Type 2 Diabetes Drugs, Panel Says

Jul 02 2008

Jardiance's Cardiovascular Benefit Claim Bodes Well For Other Products Too

Dec 05 2016

Diabetes Outcomes Trial Requirement Looks 'Increasingly Wise' – FDA’s Temple

Sep 01 2016

Will CV Verdicts For <em>Onglyza</em>, <em>Nesina</em> Cause FDA To Change Its Tune On Antidiabetic Safety?

Sep 09 2013

Jardiance Mortality Claim Narrowly Endorsed By FDA Advisory Committee

Jun 29 2016

Related Companies

Novo Nordisk A/S

Boehringer Ingelheim GmbH

Eli Lilly and Company

Bristol Myers Squibb Company

AstraZeneca PLC

Takeda Pharmaceutical Co. Ltd.

Additional Topics

United States Advisory Committees Clinical Trials Drug Safety Regulation FDA Drug Approval Standards Metabolic Disorders BioPharmaceutical

More from US FDA Performance Tracker

More from Regulatory Trackers

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window